Back to the top

Break Through Cancer and Revolution Medicines Collaborate to Study Biomarkers for RAS(ON) Inhibitor in Pancreatic Cancer

News Release For Immediate Release Media Contact: Kari McHugh Kari.McHugh@breakthroughcancer.org   Collaboration with Revolution Medicines to Study Biomarkers for RAS(ON) Multi-Selective Inhibitor in Pancreatic Cancer The expanded phase 1 clinical trial is using serial biopsies and blood samples to analyze the tumor response to RMC-6236 at an unprecedented level of detail.   (CAMBRIDGE, MASS.) December 19, 2024 – Break Through Cancer has launched a collaborative cohort for a Phase 1 study of RMC-6236, a compound developed by Revolution Medicines that is designed to suppress multiple RAS proteins that drive human cancers, including pancreatic cancer, non-small cell lung cancer and colorectal......

Continue reading

Break Through Cancer Launches Team to Prevent Lung Cancer Recurrence with the Hope of Long-term Cures.

News Release For Immediate Release Media Contact: Kari McHugh Kari.McHugh@breakthroughcancer.org   Break Through Cancer Launches Team to Prevent Lung Cancer Recurrence with the Hope of Long-term Cures. Top cancer researchers unite in radical collaboration to target residual lung cancer cells remaining after initial therapy. (CAMBRIDGE, MASS.) December 05, 2024 – Lung cancer is the leading cause of cancer death worldwide, with various subtypes affecting millions of people each year. Among these, ALK-positive lung cancer frequently strikes younger people who have never smoked, including those aged between 20 and 50. Upon diagnosis, 80% of individuals already have stage 4 metastatic cancer,......

Continue reading

Break Through Cancer Announces First Patient Enrolled in Phase 2 Trial Targeting Residual Disease in AML

News Release For Immediate Release Media Contact: Kari McHugh Kari.McHugh@breakthroughcancer.org   Break Through Cancer Announces First Patient Enrolled in Phase 2 Trial  Targeting Residual Disease in AML The novel study explores the effects of menin inhibition in acute myeloid leukemia with minimal residual disease as an endpoint. (CAMBRIDGE, MASS.) November 1, 2024 – Break Through Cancer, a Boston-based cancer research foundation, has launched a clinical trial to explore if an investigational drug can eliminate minimal residual disease (MRD) in acute myeloid leukemia (AML). AML often responds well to initial treatment, but residual cancer cells frequently cause relapse. Break Through Cancer’s......

Continue reading

No More “Wait and See”: Two Clinical Trials Target the Origins of Recurrent Ovarian Cancer

News Release For Immediate Release Media Contact: Kari McHugh Kari.McHugh@breakthroughcancer.org   No More “Wait and See”: Two Clinical Trials Target the Origins of Recurrent Ovarian Cancer Break Through Cancer scientists are evaluating a “second-look” technique to measure and destroy persistent cancer cells resistant to frontline chemotherapy. (CAMBRIDGE, MASS.) September 26, 2024 – After initial therapy to treat ovarian cancer, a small number of cancer cells, undetectable on scans, often linger in the body. These cells, referred to as minimal residual disease (MRD), are the seed from which cancer can and does recur for most women diagnosed with stage III or......

Continue reading

Break Through Cancer and ALK Positive, Inc. Team Up to Conquer ALK-Positive Lung Cancer with a $2 Million, Multi-year, Research Partnership

News Release For Immediate Release Media Contact: Kari McHugh Kari.McHugh@breakthroughcancer.org   Break Through Cancer and ALK Positive, Inc. Team Up to Conquer ALK-Positive Lung Cancer with a $2 Million, Multi-year, Research Partnership   CAMBRIDGE, MA, May 9, 2024 /Break Through Cancer announces a new partnership with ALK Positive Inc. (ALK Positive), a foundation funded by patients with ALK-positive lung cancer and their families. ALK Positive and Break Through Cancer are joining forces to fund a new initiative in lung cancer research with the hope of creating durable responses and cures for patients with ALK-positive lung cancer. ALK Positive is the......

Continue reading

Radical Collaboration: Reimagining Cancer Team Science | Nature Discovery

Radical Collaboration: Reimagining Cancer Team Science By: Jesse Boehm and Tyler Jacks Here, we define a future of cancer team science adopting “radical collaboration”—in which six “Hallmarks of Cancer Collaboration” are utilized to propel cancer teams to reach new levels of productivity and impact in the modern era. This commentary establishes a playbook for cancer team science that can be readily adopted by others. Read More at Cancer Discovery...

Continue reading

Breakthroughs In The Battle Against Cancer With Tyler Jacks | Health Gig Podcast

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 in the Battle Against Cancer with Tyler Jacks This week, explore the world of cutting-edge cancer research with Doro, Tricia, and guest Tyler Jacks, PhD, President of Break Through Cancer. Together, they discuss the organization's patient-centric approach and the proactive ways Break Through Cancer is propelling scientific breakthroughs. Dr. Jacks shares innovative approaches to early-stage cancer prevention and the discoveries Break Through Cancer has made in pancreatic cancer, glioblastoma, ovarian cancer, and more. Throughout the conversation, experience the passion and hope for a cancer-free future. Hear on SoundCloud...

Continue reading

Removing fallopian tubes can prevent ovarian cancers without causing menopause. But who’s eligible? | WBUR

JTNDaWZyYW1lJTIwd2lkdGglM0QlMjIxMDAlMjUlMjIlMjBoZWlnaHQlM0QlMjIxMjQlMjIlMjBzY3JvbGxpbmclM0QlMjJubyUyMiUyMGZyYW1lYm9yZGVyJTNEJTIybm8lMjIlMjBzcmMlM0QlMjJodHRwcyUzQSUyRiUyRnBsYXllci53YnVyLm9yZyUyRmhlcmVhbmRub3clMkYyMDIzJTJGMDMlMkYxNiUyRm92YXJpYW4tY2FuY2Vycy1mYWxsb3BpYW4tdHViZXMlMjIlM0UlM0MlMkZpZnJhbWUlM0U=Removing fallopian tubes can prevent ovarian cancers without causing menopause. But who's eligible? The American Cancer Society estimates that more than 19,000 women will be diagnosed with ovarian cancer this year. More than 13,000 of them will die from the disease, which is difficult to diagnose and to treat. That's why the Ovarian Cancer Research Alliance recommended earlier this year that women (particularly those done having children) consider adding surgery to remove their fallopian tubes to pelvic surgeries like hysterectomies or tubal ligations since most ovarian cancers start in the tubes. Among those performing the surgery is Dr. Michael Worley,......

Continue reading

More physicians are calling for fallopian tube removal to prevent ovarian cancer | STAT

More physicians are calling for fallopian tube removal to prevent ovarian cancer By Zeina Mohammed — Boston GlobeFeb. 23, 2023 Ovarian cancer has long been one of the deadliest cancers to strike women. No tests are available to detect it early, so most patients are diagnosed in later stages, when the cancer is more likely to have spread. Fewer than half of women survive 5 years past their diagnosis, and 80 percent have no known risk factors. Now, a growing chorus of physicians is recommending a procedure that can significantly reduce the chances of developing ovarian cancer. The procedure is......

Continue reading

Fallopian tube removal advised for more women to prevent ovarian cancer | Washington Post

In some cases, those who are done with childbearing may be advised to have tubes removed if they are having another gynecological surgery anyway By Teddy Amenabar, Amy Goldstein and Lindsey Bever To prevent more cases of ovarian cancer, a major research and advocacy group is suggesting an aggressive prevention strategy: remove a woman’s fallopian tubes if she is undergoing pelvic surgery for another reason. The practice would apply to women, trans men or nonbinary people at average risk who don’t plan to have any or additional children. The fallopian tubes are hollow structures that allow eggs to travel from......

Continue reading